Company Overview

Arecor is a globally focused biopharmaceutical company that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying the Group’s innovative proprietary formulation technology platform, Arestat™, the Group is developing an internal portfolio of proprietary products, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their partners’ therapeutic products, supported by an extensive patent portfolio.

The Group is a revenue-generating commercially-focused business with the potential to derive future revenue from multiple existing and future partnering opportunities. The Group’s strategy is to develop an internal portfolio of enhanced proprietary products to a defined value inflexion point prior to partnering with major pharmaceutical and biotechnology companies under a revenue-generating licence model with the potential for the Group to receive royalties and milestone payments. The Group also operates under a technology licensing arrangement when developing enhanced reformulations of its partners’ products, with the potential for milestone and royalty payments.

The Group’s current focus of internal proprietary product development can be divided into two product classes: diabetes and specialty hospital care. In addition, the Group also develops novel enhanced formulations of its partners’ biological products that include biosimilars, biological products and vaccines, which are derived from the Group’s formulation development and technology licensing programmes and are referred to as “Technology Partnerships”.

Arecor Interims Results Presentation

8 September 2022

Latest documents

Proactive Investors interview – Arecor Therapeutics “looking forward to another successful year”

19 January 2023

Trinity Delta – Hikma licence milestone achieved

13 January 2023

Trinity Delta – Getting the chemistry right

20 December 2022